Phenex Pharmaceuticals is a drug discovery and development company focussed on the target class of nuclear receptors for the development of novel pharmaceuticals. Phenex currently pursues two independent small molecule programs targeting nuclear receptors: - FXR agonists for the treatment of the Metabolic Syndrome and Non-alcoholic Steatohepatitis (NASH). - RORyt antagonists for the treatment of a range of autoimmune diseases such as Rheumatoid Arthritis or Multiple Sclerosis.